search
Back to results

Western Equine Encephalitis Vaccine, Inactivated (WEE)

Primary Purpose

Virus

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Western Equine Encephalitis Vaccine
Sponsored by
U.S. Army Medical Research and Development Command
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Virus

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 18-55 years of age
  • In good health as determined by pertinent medical history, brief physical exam, vital signs, and clinical safety laboratory evaluations
  • Female: has a negative urine pregnancy test and is willing to use reliable form of contraception for the study duration
  • Negative HIV antibody screen, seronegative for HBsAg and Hepatitis C antibody
  • WEE, EEE, VEE, and CHIK PRNT80<1:10
  • Ability to comprehend abnd a willingness to sign an informed consent, which includes the HIPAA and a separate HIV consent form
  • Be willing to comply with all follow-up visits, testing, and AE reporting

Exclusion Criteria:

  • Participant in the USAMRIID SIP
  • Receipt of any other vaccine or investigational; drug within 30 days prior to study entry
  • Anticipates receipt of other vaccines for the duration of the study (influenza vaccination will be permitted but not within 28 days of WEE vaccination
  • Acute of chronic medical conditions, medications, or dietary supplements that, in the PI's opinion, would impair the subject's ability to respond to vaccination
  • Hypersensitivity to any vaccine
  • Allergic to any vaccine component: Human serum albumin, Neomycin
  • Receipt of or anticipates receipt of blood products during the study
  • Female: Pregnant or breastfeeding
  • Clinically significant abnormal laboratory tests (generally greater than or equl to 2 times the upper limit of normal as determined by the PI)

Sites / Locations

  • Clinical Research Unit, Division of Medicine, USAMRIID

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Vaccinated

Arm Description

Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)

Outcomes

Primary Outcome Measures

Subjects Reporting Adverse Events by Vaccination and Sex

Secondary Outcome Measures

Immunogenicity
The primary endpoint used to measure immunogeniciyt of the WEE vaccine, the 80% plaque-reduction neautralization titer (PRNT 80), will be evaluated for subjects in the per protocol population. The secondary endpoint will be GMT, with 95% CI, of the PRNT 80 for WEE-specific antibodies at each scheduled timepoint.

Full Information

First Posted
July 8, 2010
Last Updated
April 25, 2019
Sponsor
U.S. Army Medical Research and Development Command
search

1. Study Identification

Unique Protocol Identification Number
NCT01159561
Brief Title
Western Equine Encephalitis Vaccine, Inactivated
Acronym
WEE
Official Title
Phase 1 Study to Evaluate the Safety and Immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, In Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
March 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
U.S. Army Medical Research and Development Command

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to determine the safety and immunogenicity of WEE Vaccine Lot number 3-1-92.
Detailed Description
Study Objectives: Primary: To assess safety of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, lot 3-1-92. Secondary: To evaluate immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, lot 3-1-92.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Virus

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vaccinated
Arm Type
Experimental
Arm Description
Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)
Intervention Type
Biological
Intervention Name(s)
Western Equine Encephalitis Vaccine
Intervention Description
Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
Primary Outcome Measure Information:
Title
Subjects Reporting Adverse Events by Vaccination and Sex
Time Frame
28 days following each vaccination
Secondary Outcome Measure Information:
Title
Immunogenicity
Description
The primary endpoint used to measure immunogeniciyt of the WEE vaccine, the 80% plaque-reduction neautralization titer (PRNT 80), will be evaluated for subjects in the per protocol population. The secondary endpoint will be GMT, with 95% CI, of the PRNT 80 for WEE-specific antibodies at each scheduled timepoint.
Time Frame
Baseline and multiple dates throughout study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18-55 years of age In good health as determined by pertinent medical history, brief physical exam, vital signs, and clinical safety laboratory evaluations Female: has a negative urine pregnancy test and is willing to use reliable form of contraception for the study duration Negative HIV antibody screen, seronegative for HBsAg and Hepatitis C antibody WEE, EEE, VEE, and CHIK PRNT80<1:10 Ability to comprehend abnd a willingness to sign an informed consent, which includes the HIPAA and a separate HIV consent form Be willing to comply with all follow-up visits, testing, and AE reporting Exclusion Criteria: Participant in the USAMRIID SIP Receipt of any other vaccine or investigational; drug within 30 days prior to study entry Anticipates receipt of other vaccines for the duration of the study (influenza vaccination will be permitted but not within 28 days of WEE vaccination Acute of chronic medical conditions, medications, or dietary supplements that, in the PI's opinion, would impair the subject's ability to respond to vaccination Hypersensitivity to any vaccine Allergic to any vaccine component: Human serum albumin, Neomycin Receipt of or anticipates receipt of blood products during the study Female: Pregnant or breastfeeding Clinically significant abnormal laboratory tests (generally greater than or equl to 2 times the upper limit of normal as determined by the PI)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronald B Reisler, MD
Organizational Affiliation
USAMRIID Medical Division
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Research Unit, Division of Medicine, USAMRIID
City
Fort Deterick
State/Province
Maryland
ZIP/Postal Code
21702-5011
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
33240257
Citation
Keshtkar-Jahromi M, Reisler RB, Haller JM, Clizbe DP, Rivard RG, Cardile AP, Pierson BC, Norris S, Saunders D, Pittman PR. The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity. Front Immunol. 2020 Nov 9;11:555464. doi: 10.3389/fimmu.2020.555464. eCollection 2020.
Results Reference
derived

Learn more about this trial

Western Equine Encephalitis Vaccine, Inactivated

We'll reach out to this number within 24 hrs